Repatha Market Report 2026

Repatha Market Overview

• The Repatha market growth in the historic period has been driven by increasing prevalence of hyperlipidemia, limitations of statin-only therapies • Market expansion is supported by increasing demand for advanced cardiovascular treatments, rising adoption of combination lipid management strategies • Growth Driver: Rising Prevalence Of Cardiovascular Diseases Driving Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Repatha Market?

Repatha (evolocumab) is a monoclonal antibody used to lower cholesterol levels in patients with hyperlipidemia. It works by inhibiting PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the blood. Repatha is often prescribed for individuals who are unable to achieve desired cholesterol levels through diet or statin therapy alone. The main indications of repatha are primary hypercholesterolemia, homozygous familial hypercholesterolemia (FH), and atherosclerotic cardiovascular disease (CVD). Primary hypercholesterolemia is a condition of elevated blood cholesterol, primarily due to genetic or lifestyle factors, increasing cardiovascular disease risk. It is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies and is used by various end users including pediatric, adult, and geriatric.

What Is The Repatha Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for advanced cardiovascular treatments, rising adoption of combination lipid management strategies, expansion of preventive cardiology practices, growing focus on personalized cholesterol management, increasing investment in biologic drug development. Major trends in the forecast period include increasing adoption of pcsk9 inhibitors, rising use of injectable lipid-lowering therapies, growing focus on cardiovascular risk reduction, expansion of biologic cholesterol treatments, enhanced emphasis on long-term lipid management.

Global Repatha Market Segmentation

1) By Indication: Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (FH), Atherosclerotic Cardiovascular Disease (CVD) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Repatha Market?

The growing prevalence of cardiovascular diseases is expected to propel the growth of the repatha market going forward. Cardiovascular diseases (CVDs) refer to a group of conditions affecting the heart and blood vessels, including coronary artery disease, heart attacks, strokes, and hypertension. The prevalence of cardiovascular diseases (CVDs) is attributed to factors such as poor diet, lack of physical activity, smoking, excessive alcohol consumption, high blood pressure, and genetic predisposition. Repatha (evolocumab) treats cardiovascular diseases by lowering LDL cholesterol levels, reducing the risk of heart attacks, strokes, and other cardiovascular events in patients with high cholesterol or atherosclerotic cardiovascular disease. For instance, in September 2024, according to the British Heart Foundation, a UK-based cardiovascular research charity, in the UK, approximately 7.6 million individuals are currently affected by heart and circulatory diseases, comprising 4 million men and 3.6 million women. By 2030, this number could increase by 1 million, and by 2040, it may rise to 2 million more than the current figures. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the repatha industry. The rising prevalence of high cholesterol is expected to fuel the growth of the repatha market going forward. High cholesterol refers to elevated levels of low-density lipoprotein (LDL) cholesterol in the blood, which increases the risk of cardiovascular diseases such as heart attacks, strokes, and coronary artery disease. The prevalence of high cholesterol is attributed to factors such as poor diet, lack of physical activity, genetics, obesity, smoking, and excessive alcohol consumption. Repatha (evolocumab) reduces high cholesterol by inhibiting a protein called PCSK9, which increases the liver's ability to remove LDL (bad) cholesterol from the bloodstream. This results in a significant reduction in LDL cholesterol levels. For instance, in August 2025, according to BioMed Central (BMC), a UK-based open-access academic publisher, the global prevalence was 28.8% for hypertriglyceridemia, 24.1% for hypercholesterolemia, 38.4% for low HDL-C, and 18.93% for high LDL-C. Men presented a higher prevalence of hypertriglyceridemia (33.8% vs. 24.5% in women), while women showed a higher frequency of low HDL-C (40.5% vs. 34.1% in men). Therefore, the rising prevalence of high cholesterol is driving the growth of the repatha industry. The rising obesity rate is expected to accelerate the growth of the repatha market going forward. The obesity rate refers to the percentage of individuals in a population who are classified as obese, based on their body mass index (BMI). The rising obesity rate is attributed to factors such as poor dietary habits, increased consumption of processed and high-calorie foods, sedentary lifestyles, lack of physical activity, and genetic predisposition. Repatha is being explored as a potential treatment for obesity by helping to reduce cholesterol levels and improve metabolic health, though its primary use remains in managing hyperlipidemia. For instance, in November 2025, according to the Organisation for Economic Co operation and Development, a France-based intergovernmental organization (IGO), reported that the proportion of the population with obesity increased from 13% to 19% on average across OECD countries. Therefore, the rising obesity rate is driving the growth of the repatha industry.

Key Players In The Global Repatha Market

Major companies operating in the repatha market are Amgen Inc.

Regional Insights

North America was the largest region in the repatha market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Repatha Market?

The repatha market consists of sales of repatha injections and repatha pre-filled pens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Repatha Market Report 2026?

The repatha market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the repatha industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.